Provided by Tiger Trade Technology Pte. Ltd.

Ironwood Pharmaceuticals

3.06
-0.0900-2.86%
Post-market: 3.080.0180+0.59%19:13 EDT
Volume:1.35M
Turnover:4.16M
Market Cap:497.80M
PE:20.62
High:3.20
Open:3.10
Low:3.03
Close:3.15
52wk High:5.78
52wk Low:0.5271
Shares:162.68M
Float Shares:118.09M
Volume Ratio:0.32
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1484
EPS(LYR):0.1484
ROE:-574.72%
ROA:19.85%
PB:-1.90
PE(LYR):20.62

Loading ...

Craig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD)

TIPRANKS
·
Mar 19

Ironwood Pharmaceuticals director Alexander J. Denner disposes of shares worth USD 20.53 million

Reuters
·
Mar 18

BRIEF-Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10

Reuters
·
Mar 11

Ironwood Pharmaceuticals Inc - Maturity Date for Revolving Credit Facility Remains December 31, 2028 - SEC Filing

THOMSON REUTERS
·
Mar 11

Ironwood Pharmaceuticals extends revolving credit facility maturity to Dec. 31, 2028

Reuters
·
Mar 11

Ironwood Pharmaceuticals to Join Fireside Chat at The Citizens Life Sciences Conference

Reuters
·
Mar 05

Ironwood Pharmaceuticals Is Maintained at Market Outperform by Citizens

Dow Jones
·
Feb 26

Ironwood Pharmaceuticals Balances Growth Plans With Pricing Risks

TIPRANKS
·
Feb 26

Ironwood Pharmaceuticals Q4 Adj. EPS $(0.01) Misses $0.01 Estimate, Sales $47.709M Miss $50.933M Estimate

Benzinga
·
Feb 25

BRIEF-Ironwood Pharmaceuticals Q4 Revenue USD 47.709 Million

Reuters
·
Feb 25

Ironwood Pharmaceuticals Inc: Reiterates 2026 Outlook

THOMSON REUTERS
·
Feb 25

Ironwood Pharmaceuticals Q4 Adjusted Net Income USD -2.274 Million

THOMSON REUTERS
·
Feb 25

Ironwood Pharmaceuticals Q4 Basic EPS USD -0.01

THOMSON REUTERS
·
Feb 25

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

THOMSON REUTERS
·
Feb 25

Ironwood Pharmaceuticals Inc expected to post earnings of 1 cent a share - Earnings Preview

Reuters
·
Feb 23

Ironwood Pharmaceuticals Inc. published an update to their financial calendar

Reuters
·
Feb 19

Ironwood Pharmaceuticals Principal Accounting Officer Ronald Silver Reports Disposal of Common Shares

Reuters
·
Jan 08

Why Ironwood Pharmaceuticals (IRWD) Is Up 37.8% After New 2026 Guidance And Ferring Settlement

Simply Wall St.
·
Jan 06

Ironwood Pharmaceuticals Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Jan 05

NASD Most Active Issues

Dow Jones
·
Jan 03